Your email has been successfully added to our mailing list.

×
0 0 0 0 0 -0.0455172413793104 -0.0586206896551724 -0.0758620689655172
Stock impact report

Intellia Therapeutics lands genome editing technology patent in Europe [Seeking Alpha]

Intellia Therapeutics, Inc. (NTLA) 
Last intellia therapeutics, inc. earnings: 2/27 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intelliatx.com/investor-overview
Company Research Source: Seeking Alpha
Intellia Therapeutics (NASDAQ: NTLA ) announces that the European Patent Office granted a patent broadly covering the CRISPR/Cas9 genome editing technology. The patent includes claims covering compositions of the widely adopted CRISPR single guide RNA technology for use in any non-cellular and cellular setting, including eukaryotic cells such as human or mammalian cells, as well as for use in human therapeutics. The company says third parties have nine months to challenge the patent. NTLA premarket to $14.50. Source: Press Release Now read: Gilead Sciences: A Core Buy In Biotech With Several Potential Value Drivers » Show less Read more
Impact Snapshot
Event Time:
NTLA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for NTLA alerts
Opt-in for
NTLA alerts

from News Quantified
Opt-in for
NTLA alerts

from News Quantified